Aspire Biopharma Holdings, Inc. · NASDAQ:ASBP
Aspire Biopharma — Investor Presentation (March 2026)
23 slides from Aspire Biopharma's investor presentation, March 2026
Slide 1: Investor Presentation
March 2026 Investor Presentation Nasdaq: ASBP
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by t
Slide 3: Aspire at a Glance
Aspire at a Glance Patent-pending drug delivery technology for rapid sublingual absorption and entry into the bloodstream of drugs and supplements ▪ Enhances the pharmacokinetic performance of Active Pharmaceutical Ingredients (“APIs”), supplements and nutraceuticals into the bloodstream, increasing
Slide 4: Drug and Supplement Delivery Technology Innovator
Drug and Supplement Delivery Technology Innovator Aspire Biopharma has developed Technology delivers fast acting New mechanism of delivery disruptive technologies for drug formulations using our allows rapid sublingual delivering drugs and other absorption into the products sublingually(1). patent-p
Slide 5: Drug and Supplement Delivery Technology Innovator
Drug and Supplement Delivery Technology Innovator Fast Acting Powder-form medication developed using our patent-pending technology enters the bloodstream in a fraction of the time as compared to oral tablets and capsules Easy to Use Dissolves easily under the tongue Dosage Management Drugs avoid fir
Slide 6: Aspire’s Mechanisms of Action
Aspire’s Mechanisms of Action Mouth to Blood Stream Pathways Nature Provides the Mouth with Direct Access to Blood Stream Dorsalis Lingual Artery Lingual Vein Aspire’s sublingual delivery system avoids the Veins of Dorsum of Tongue side effect drugs delivered in pills or tables orally ▪ Avoid damage
Slide 7: Overview – The Technology
Overview – The Technology Aspire's Patent Pending Sublingual Technology Video 7
Slide 8: Aspire Pipeline, Commercial Opportunities & Planned 2026 Milestones
Aspire Pipeline, Commercial Opportunities & Planned 2026 Milestones Aspirin Products Non-Aspirin Prescription Drug Products High Dose ▪ Alprazolam (Generic Xanax®): Formulation for sublingually administration of drug for ✓ Completed clinical trial to evaluate the pharmacodynamic effect of a treatmen
Slide 9: Aspire Patent Portfolio
Aspire Patent Portfolio Sublingual Aspirin Product Candidate • Filed provisional patent applications with the USPTO on March 31, 2023 and October 2, 2024, respectively, pertaining to Oral Mucosal Formulations of Aspirin that utilize Aspire’s fast acting formulation. Omnibus Patent Filing • Filed an
Slide 10: Global Market Opportunity for Target Product Portfolio
Global Market Opportunity for Target Product Portfolio Aspire believes its disruptive technology can be applied to a number of approved drugs and supplements Global Analgesics Market Valued at $47.32B in 2023 and projected to reach $75.73B by 2032, growing at a compound annual growth rate (CAGR) of
Slide 11: Sublingual Aspirin Product: Background
Sublingual Aspirin Product: Background Oral aspirin (ASA) with its anti-inflammatory properties has been used world-wide for over 100 years Aspirin is one of the most-studied and understood drugs and universally approved for use. In the past Aspirin-induced GI bleeding has limited the long-term oral
Slide 12: Sublingual Aspirin Product: Clinical Trial
Sublingual Aspirin Product: Clinical Trial Strategy Aspire uses existing, approved generic-drug dosages. Generic drugs do not need to repeat the clinical trials related to active ingredients but must demonstrate sublingual route of administration as it pertains to: • effectiveness • amount of drug t
Slide 13: Sublingual Aspirin Product: Overview and Top-Line Clinical Results
Sublingual Aspirin Product: Overview and Top-Line Clinical Results Study Design and Top-Line Results Plasma ASA Concentrations (ng/mL) over 30 Minutes after ▪ Primary objective of the clinical trial was to evaluate the bioavailability Dosing of acetylsalicylic acid (ASA, the active antiplatelet form
Slide 14: Sublingual Aspirin Product: Overview and Top-Line Clinical Results
Sublingual Aspirin Product: Overview and Top-Line Clinical Results Mean Serum TxB2* Concentrations (ng/mL) (lower concentrations mean less platelet aggregation) over 30 Minutes after Dosing OTASA BA2038 (Aspire Additional Important Clinical Trial Findings sublingual aspirin granules), OTASA BA002039
Slide 15: Sublingual Aspirin Product Commercialization and Go-to-Market Strategy
Sublingual Aspirin Product Commercialization and Go-to-Market Strategy Launch product initially in the Rx market, likely through licensing or partnering agreements Partner with an experienced end-to-end marketing and distribution firms Significant potential licensing opportunities with leading drug
Slide 16: Sublingual Aspirin Product: Analgesics Market Opportunity
Sublingual Aspirin Product: Analgesics Market Opportunity Non-opioid analgesic and opioid markets combined currently estimated at $80+B and projected to grow to nearly $100B in five years 2022 2023 2024 2025 2026 2027 Market Data ($-Bil) Opioids $32.5 $33.6 $34.6 $35.7 $36.8 $37.9 Analgesics $48.0 $
Slide 17: BUZZ BOMB New Caffeine Product
BUZZ BOMB New Caffeine Product • Single serving 50mg caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, co
Slide 18: BUZZ BOMB New Caffeine Product
BUZZ BOMB New Caffeine Product New BUZZ BOMB E-Commerce Website Landing Page BUZZ BOMB Newly Designed Packaging 18
Slide 19: BUZZ BOMB Disruptive Characteristics
BUZZ BOMB Disruptive Characteristics BUZZ BOMB Caffeine Benefits: • Speed: works nearly immediately (less than 2 minutes) vs. 20-30 minutes • Convenience: small, easy to use single-use packets (no mixing and measuring for beverages) • Energy management: use as needed to precisely manage caffeine int
Slide 20: BUZZ BOMB Buzz at the Fitness Conventions
BUZZ BOMB Buzz at the Fitness Conventions 20
Slide 21: Pre-Workout Supplement Market
Pre-Workout Supplement Market • Global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030 driven by: ❖ Rising fitness culture and gym memberships ❖ Consumer focus on performance and recovery ❖ Expanding demographics (women, G
Slide 22: Aspire’s Investment Considerations
Aspire’s Investment Considerations ▪ Multiple ℞ applications in heart attack/stroke, anti-anxiety, antiplatelet, nausea and others ▪ Large Addressable ℞ Markets ▪ High Dose Aspirin Prescription Product: Trial demonstrated dramatically higher and more rapid therapeutic impact compared to standard che
Slide 23: Thank You.
Aspire BioPharma Holdings, Inc. 23150 Fashion Drive, Suite 232 Thank You. Estero, FL 33928 www.aspirebiolabs.com info@aspire-biopharma.com Investor Relations Kevin McGrath PCG Advisory kevin@pcgadvisory.com Nasdaq: ASBP 23
Aspire Biopharma Holdings — Investor Presentation (March 2026) on 6ix